Somalogic
Standard BioTools Q1 Revenues Grow 81 Percent After SomaLogic Merger
Revenues grew 2 percent year over year on a pro forma basis following the completion of the merger with SomaLogic in early January.
In Brief This Week: SomaLogic, Standard BioTools, Qiagen, Geneseeq
News items for the week of Jan. 1, 2024.
SomaLogic Cofounder and former CEO Larry Gold and Chief Technology Officer Jason Cleveland have filed a class action suit, accusing the board of breach of fiduciary duty.
SomaLogic Raises Full-Year 2023 Guidance on 14 Percent Q3 Core Revenue Growth
The proteomics firm beat Wall Street estimates on the top and bottom lines, though total revenues were down 47 percent due to a royalty payment last year.
The firms' merger agreement, filed with the US Securities and Exchange Commission, contradicts previous messaging on layoffs at Standard BioTools.
Oct 4, 2023
Standard BioTools, SomaLogic to Merge
May 13, 2022
May 12, 2022
SomaLogic Q1 Revenues Grow 22 Percent
Mar 30, 2022
Jan 6, 2022